相关实验视频
Updated: Jul 25, 2025

05:23
Investigating Migraine-Like Behavior Using Light Aversion in Mice
Published on: August 11, 2021
3.8K
在CGRP之外的偏头痛治疗的未来目标
Linda Al-Hassany1, Deirdre M Boucherie1, Hannah Creeney2
1Department of Internal Medicine, Division of Vascular Medicine and Pharmacology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
The journal of headache and pain
|June 27, 2023
概括
研究探讨了对偏头痛的非素基因相关 (CGRP) 标,确定了潜在的途径,如metabotropic受体和离子通道. 虽然目前的治疗方法显示了模两可的结果,但这些研究为未来的治疗提供了对偏头痛机制的见解.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛是一种慢性神经血管疾病,其中三角血管激活和CGRP释放是关键.
- 现有的CGRP ((-受体) 疗法对很大一部分患者是无效的,需要替代治疗点.
- 本综述全面审查了偏头痛病理生理学中的潜在非CGRP目标.
研究的目的:
- 审查非CGRP目标在偏头痛中的病理生理学作用.
- 确定对CGRP向治疗无反应的偏头痛患者的替代治疗策略.
主要方法:
- 科学文献的叙述性审查.
- 目标的分析包括metabotropic受体 (PACAP,VIP,氨酸,上腺素),细胞内标 (NO,PDE3,PDE5) 和离子通道 (,,TRP,ASIC).
主要成果:
- 甲基受体,NO和某些离子通道 (,TRP,ASIC) 涉及偏头痛类发作,研究程度各不相同.
- 现有的药物向PACAP,NO和一些道;其他药物有间接作用或缺乏选择性剂.
- 对PACAP,NO,通道,TRP通道和PAC1抗体的临床试验产生了模两可的结果.
结论:
- 非CGRP目标为偏头痛机制提供了宝贵的见解,尽管尚未产生有效的治疗方法.
- 对这些替代目标进行进一步的研究对于对CGRP疗法的不响应者至关重要.
- 最终的目标是开发新的治疗方法,以实现未来无偏头痛的未来.
相关概念视频
Direct-Acting Cholinergic Agonists: Therapeutic Uses
797
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
797
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.4K
Open Angle Glaucoma: Treatment
481
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
481
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
208
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
208
Targets for Drug Action: Overview
6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K
G Protein-coupled Receptors
12.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
12.3K

